A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.

Medicine (Baltimore) · 2021 · PMC8084035 · PMID 33907099

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 2 ] This comparison of multiple three-drug regimens found that groups using oxaliplatin or capecitabine, rather than cisplatin or 5-Fu, showed a trend toward longer overall survival and improved safety.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.